Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Visual acuity of children treated with chemotherapy for optic pathway gliomas.

Pediatric blood & cancer - 1 Feb 2014

Kalin-Hajdu Evan, Décarie Jean-Claude, Marzouki Monia, Carret Anne-Sophie, Ospina Luis H

Abstract excerpt

BACKGROUND: Chemotherapy is the most common primary treatment modality for pediatric optic pathway gliomas (OPGs). Due to the risk of severe visual impairment, visual acuity (VA) has become a clinical parameter of fundamental importance for children with OPGs. Despite this reality, most studies omit crucial information necessary for analysis of the effect of chemotherapy on VA in patients with cerebral gliomas....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Genes, Neurofibromatosis 1

Share to Neoplasm Staging

Share to Neurofibromatosis 1

Share to Vision Disorders

Share to Visual Acuity

Source

Identifiers

PMID: 23956233
DOI: 10.1002/pbc.24726

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Visual acuity of children treated with chemotherapy for optic pathway gliomas.PMID 23956233Read ↗

Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.Semantic proximity Read ↗

An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic StrategiesSemantic proximity Read ↗

Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center studySemantic proximity Read ↗

Recent advances in optic nerve glioma with a focus on the young patient.Semantic proximity Read ↗

Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.Semantic proximity Read ↗

Nerve Growth Factor Eye Drops for Optic Pathway Gliomas: Four-Year Follow-Up Findings in Children After a Single Treatment CourseSemantic proximity Read ↗

Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases.Semantic proximity Read ↗

Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1.Semantic proximity Read ↗

Clinical signs and genetic evaluation of patients with neurofibromatosis type 1 with and without optic pathway gliomas in a center in Turkey.Semantic proximity Read ↗

A 10‐year experience of outcome in chemotherapy‐treated hereditary retinoblastomaSemantic proximity Read ↗

Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2.Semantic proximity Read ↗

Distinguishing optic pathway glioma and retinitis pigmentosa with visual field testing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.